Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Intec Pharma Ltd. (NTEC)

(Delayed Data from NSDQ)

$6.24 USD

+0.02 (0.32%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Indaptus Therapeutics, Inc. [NTEC]

Reports for Purchase

Showing records 1 - 20 ( 78 total )

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/04/2021

Pages: 4

Recent Progress, But We Remain on the Sidelines; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

10/09/2020

Pages: 4

New Research Agreement Announced With Merck; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/17/2020

Pages: 4

Funding Round Completed; 2Q20 Financial Results; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/15/2020

Pages: 4

1Q20 Financials Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

04/13/2020

Pages: 4

Still Awaiting Clarity on a Second Act; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/19/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/18/2020

Pages: 7

4Q19 Recap - Waiting for Data Points

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

12/12/2019

Pages: 4

Novartis Drops Collaboration, as Expected; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/02/2019

Pages: 4

Outlook Remains Uncertain; 3Q19 Financials; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/15/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/14/2019

Pages: 7

3Q19 Recap - Partnership for AP-CD/ LD?

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/11/2019

Pages: 7

Neutral Pending Visibility

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

10/11/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/12/2019

Pages: 4

2Q19 Financial Results Reported; Route Ahead Remains Unclear; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/07/2019

Pages: 5

ACCORDANCE Study Fails to Meet Primary or Secondary Endpoints; Downgrading to Neutral Without Target Price

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/20/2019

Pages: 5

Accordion Pill Multiple-Dose Pharmacokinetic Data Presented at Parkinson''s Disease Conference; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/28/2019

Pages: 4

1Q19 Financial Results Reported; ACCORDANCE Top-Line Data Approaching; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/08/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/08/2019

Pages: 8

1Q19 Recap - Catalysts Surfacing in 2H19

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Indaptus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/30/2019

Industry Report

Pages: 19

Cannabis - Where are we and where are we going?

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

previous
1
2
3
4
next